Aptose Biosciences Inc. Business Finance Contracts & Agreements
33 Contracts & Agreements
- Equity Distribution Agreements (3 contracts)
- Facility Agreements (1)
- Funding Agreements (1)
- Investor Rights Agreements (2)
- Purchase Agreements (1)
- Registration Rights Agreements (2)
- Share Agreements (2)
- Subscription Agreements (2)
- Underwriting Agreements (6)
- Warrant Agreements (13)
- Form of Placement Agent Warrant (Filed With SEC on November 25, 2024)
- Form of Common Warrant (Filed With SEC on November 25, 2024)
- Facility Agreement among the Company and Hanmi Pharmaceutical Co., Ltd dated August 27, 2024 (Filed With SEC on November 12, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on October 31, 2024)
- Form of Placement Agent Warrant (Filed With SEC on October 31, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on October 31, 2024)
- Form of Common Warrant (Filed With SEC on October 31, 2024)
- Amended Warrant Agreement (Filed With SEC on April 26, 2024)
- Funding Satisfaction Agreement (Filed With SEC on January 30, 2024)
- Amended and Restated Investors Rights Agreement (Filed With SEC on January 30, 2024)
- Subscription Agreement (Filed With SEC on January 30, 2024)
- Form of Underwriter Warrant (Filed With SEC on January 30, 2024)
- Form of Public Offering Warrant (Filed With SEC on January 30, 2024)
- Form of Placement Agent Warrant (Filed With SEC on January 30, 2024)
- Form of Hanmi Warrant (Filed With SEC on January 30, 2024)
- Underwriting Agreement (Filed With SEC on January 30, 2024)
- Form of Underwriters Warrant (Filed With SEC on December 29, 2023)
- Form of Underwriting Agreement (Filed With SEC on December 29, 2023)
- Form of Pre-Funded Warrant Offered in this Offering (Filed With SEC on December 11, 2023)
- Form of Warrant Offered in this Offering (Filed With SEC on December 11, 2023)
- Form of Underwriting Agreement (Filed With SEC on December 11, 2023)
- Investor Rights Agreement (Filed With SEC on September 12, 2023)
- Subscription Agreement (Filed With SEC on September 12, 2023)
- Registration Rights Agreement, dated as of May 25, 2023, by and between the Company and Keystone Capital Partners, LLC (Filed With SEC on May 26, 2023)
- Common Share Purchase Agreement, dated as of May 25, 2023, by and between the Company and Keystone Capital Partners, LLC (Filed With SEC on May 26, 2023)
- Equity Distribution Agreement, dated December 9, 2022, among Aptose Biosciences Inc. and JonesTrading Institutional Services LLC (Filed With SEC on December 12, 2022)
- Underwriting Agreement, dated July 15, 2020, between Aptose Biosciences Inc. and Piper Sandler & Co (Filed With SEC on July 16, 2020)
- Equity Distribution Agreement, dated May 5, 2020, among Aptose Biosciences Inc., Piper Sandler & Co. and Canaccord Genuity LLC (Filed With SEC on May 5, 2020)
- Underwriting Agreement, dated December 16, 2019 between Aptose Biosciences Inc. and Piper Jaffray & Co (Filed With SEC on December 17, 2019)
- Underwriting Agreement, dated May 30, 2019 among Aptose Biosciences Inc., RBC Capital Markets, LLC and Canaccord Genuity LLC (Filed With SEC on May 30, 2019)
- Equity Distribution Agreement, dated May 24, 2019, among Aptose Biosciences Inc., Piper Jaffray & Co. and Canaccord Genuity LLC (Filed With SEC on May 24, 2019)
- Form of Registration Rights Agreement dated May 7, 2019 by and between the Company and Aspire Capital Fund, LLC (Filed With SEC on May 7, 2019)
- Form of Common Share Purchase Agreement dated May 7, 2019 by and between the Company and Aspire Capital Fund, LLC (Filed With SEC on May 7, 2019)
